Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):955-956. doi: 10.1136/jnnp-2018-319410. Epub 2018 Nov 19.

Fiona Chan¹, Andrew Swayne^{1

2}, David Gillis^{3

4}, Michael Walsh¹, Robert D Henderson^{5

6}, Pamela A McCombe^{5

6}, Richard C Wong^{1

4}, Stefan Blum^{7

2}

¹ Department of Neurology, Princess Alexandra Hospital, Wooloongabba, Queensland, Australia.
² Mater Hospital Brisbane, Mater Centre for Neuroscience, South Brisbane, Queensland, Australia.
³ Department of Immunology, Sunshine Coast Hospital and Health Service, Birtinya, Queensland, Australia.
⁴ Health Support Queensland Pathology Queensland, Pathology Queensland, Herston, Queensland, Australia.
⁵ Department of Neurology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
⁶ School of Medicine, University of Queensland, St Lucia, Queensland, Australia.
⁷ Department of Neurology, Princess Alexandra Hospital, Wooloongabba, Queensland, Australia [email protected].

No abstract available

Keywords: acetylcholine receptor antibody; muscle-specific tyrosine kinase antibody; myasthenia gravis; rituximab.

Publication types